Lavipharm (LAVI) Q3 2024 earnings summary

Executive summary

• Adjusted EBITDA from continuing operations rose 21.2% year-over-year to €9.08 million for the first nine months of 2024.

• Total profit after taxes surged 338.6% to €9.22 million, driven by recognition of a deferred tax asset from subsidiary liquidation.

• Consolidated sales before clawback and rebate deductions increased 16% to €47.38 million.

Financial highlights

• Net sales reached €41.29 million, up from €36.09 million year-over-year.

• Gross profit increased 21.63% to €19.89 million.

• Adjusted earnings before taxes from continuing operations rose to €4.28 million from €2.83 million.

• Earnings before taxes from continuing operations grew to €8.89 million from €2.21 million.

Outlook and guidance

• Export activity increased by 11.4%, with domestic prescription drug sales up 28% and OTC sales up 13.8%.